Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties

Cancer Science

Volumn 97, Issue 12, 2006, Pages 1315-1320

  Yagi, Hiroshi ^a   Ueda, Masakazu ^a   Jinno, Hiromitsu ^a   Aiura, Koichi ^a   Mikami, Shuji ^a   Tada, Hiroko ^b   Seno, Masaharu ^b   Yamada, Hidenori ^b   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR PANCREATIC RIBONUCLEASE FUSION PROTEIN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE INSERTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RECOMBINANT FUSION PROTEINS; RIBONUCLEASE, PANCREATIC; TUMOR CELLS, CULTURED;

EID: 33750358149     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00336.x     Document Type: Article

References (45)

1. Lappi DA, Baird A. Mitotoxins: Growth factor-targeted cytotoxic molecules. Prog Growth Factor Res 1990; 2: 223-36.
2. Pastan II, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998; 31: 53-88.
3. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32: 2534-9.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
5. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996; 32: 2386-93.
6. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996:67-190.
7. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
8. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
9. Klagsbrun M. The fibroblast growth factor family: Structural and biological properties. Prog Growth Factor Res 1989; 1: 207-35.
10. Mason I. The ins and outs of fibroblast growth factors. Cell 1994; 78: 547-52.
11. Bikfalvi A, Klein S, Pintucci G, Rifkin D. Biological roles of fibroblast growth factor-2. Endocr Rev 1997; 18: 26-45.
12. Beck L, D'Amore P. Vascular development: Cellular and molecular regulation. FASEB J 1997; 11: 365-73.
13. Seghezzi G, Patel S, Ren C et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-73.
14. Rusnati M, Tanghetti E, Urbinati C et al. Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: Biochemical characterization and biological consequences in endothelial cell cultures. Mol Biol Cell 1999; 10: 313-27.
15. Ahmed NU, Ueda M, Ito A, Ohashi A, Funasaka Y, Ichihashi M. Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res 1997; 7: 299-305.
16. Kato J, Wanebo H, Calabresi P, Clark JW. Basic fibroblast growth factor production and growth factor receptors as potential targets for melanoma therapy. Melanoma Res 1992; 2: 13-23.
17. Lappi DA, Maher PA, Martineau D, Baird A. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J Cell Physiol 1991; 147: 17-26.
18. Lappi DA, Ying W, Barthelemy I et al. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J Biol Chem 1994; 269: 12552-8.
19. Beitz JG, Davol P, Clark JW et al. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. Cancer Res 1992; 52: 227-30.
20. Rybak SM, Saxena SK, Ackerman EJ, Youle RJ. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J Biol Chem 1991; 266: 21202-7.
21. Jinno H, Ueda M, Ozawa S et al. Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase1. Life Sci 1996; 58: 1901-8.
22. Psarras K, Ueda M, Yamamura T et al. Human pancreatic RNase1-human epidermal growth factor fusion: An entirely human 'immunotoxin analog'with cytotoxic properties against squamous cell carcinomas. Protein Eng 1998; 11: 1285-92.
23. Beintema JJ. Introduction: The ribonuclease A superfamily. Cell Mol Life Sci 1998; 54: 763-5.
24. Rybak SM, Pearson JW, Fogler WE et al. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst 1996; 88: 747-53.
25. Jinno H, Ueda M, Ozawa S et al. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines - a trial for less immunogenic chimeric toxin. Cancer Chemother Pharmacol 1996; 38: 303-8.
26. Futami J, Seno M, Kosaka M, Tada H, Seno S, Yamada H. Recombinant human pancreatic ribonuclease produced in E. coli: Importance of the amino-terminal sequence. Biochem Biophys Res Commun 1995; 216: 406-13.
27. Futami J, Tada H, Seno M, Ishikami S, Yamada H. Stabilization of human RNase1 by introduction of a disulfide bond between residues 4 and 118. J Biochem 2000; 128: 245-50.
28. Kobe B, Deisenhofer J. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. J Mol Biol 1996; 264: 1028-43.
29. Futami J, Seno M, Ueda M, Tada H, Yamada H. Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Eng 1999; 12: 1013-19.
30. Hoshimoto S, Ueda M, Jinno H, Kitajima M, Futami J, Seno M. Mechanisms of growth inhibitory effect of RNase-EGF fused proteins against EGFR-overexpressing cells. Anticancer Res 2006; 26: 857-64.
31. Tada H, Onizuka M, Muraki K et al. Insertional-fusion of basic fibroblast growth factor endowed ribonuclease 1 with enhanced cytotoxicity by steric blockade of inhibitor interaction. FEBS Lett 2004; 568: 39-43.
32. Blanckaert VD, Schelling ME, Elstad CA, Meadows GG. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res 1993; 53: 4075-81.
33. Hayashida T, Ueda M, Aiura K et al. Anti-angiogenic effect of an insertional fusion protein of human basic fibroblast growth factor and ribonuclease-1. Protein Eng Des Sel 2005; 18: 321-7.
34. Futami J, Tsushima Y, Tada H, Seno M, Yamada H. Convenient and efficient in vitro folding of disulfide-containing globular protein from crude bacterial inclusion bodies. J Biochem 2000; 127: 435-41.
35. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989; 182: 319-26.
36. Streit M, Stephen AE, Hawighorst T et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002; 62: 2004-12.
37. Leland PA, Raines RT. Cancer chemotherapy -ribonucleases to the rescue. J Chem Biol 2001; 8: 405-13.
38. Leland PA, Staniszewski KE, Kim BM, Raines RT. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 2001; 276: 43095-102.
39. Rybak SM, Newton DL. Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 1999; 253: 325-35.
40. Futami J, Maeda T, Kitazoe M et al. Preparation of potent cytotoxic ribonucleases by cationization: Enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 2001; 40: 7518-24.
41. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
42. D'Amore PA, Shima DT. Tumor angiogenesis: A physiological process or genetically determined? Cancer Metastasis Rev 1996; 15: 205-12.
43. Hori A, Sasada R, Matsutani E et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6180-4.
44. Noguchi Y, Wu J, Duncan R et al. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998; 89: 307-14.
45. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006; 98: 335-44.